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Subsequent probabilistic analyses will be used to further explore uncertainties around 
the estimates.
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HEALTH CARE RESOURCE UTILIZATION AMONG ADULTS WITH TYPE 
2 DIABETES MELLITUS, HYPERTENSION, AND OBESITY
Grandy S1, Fox KM2
1AstraZeneca LP, Wilmington, DE, USA, 2Strategic Healthcare Solutions, LLC, Monkton, MD, 
USA
OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) utilize more health 
care resources than those without diabetes, yet a portion of the increased use may be 
due to comorbid conditions. This study compared health care resource utilization 
among adults with T2DM plus hypertension (HTN) and obesity with those with 
T2DM only. METHODS: Respondents to the Study to Help Improve Early evaluation 
and management of risk factors Leading to Diabetes (SHIELD), a large US survey, 
self-reported their height, weight, comorbid conditions, number of hospitalizations, 
emergency department (ED) visits, and physician visits in the past 12 months. Respon-
dents reporting T2DM and HTN and obesity (body mass index [BMI] ≥30 kg/m2) 
were identiﬁed and compared with a T2DM-only group. RESULTS: T2DM respon-
dents with, comorbid HTN, and obesity (n = 1186), were younger, more likely to be 
men, and had lower income but were similar to T2DM-only respondents (n = 293) in 
race, education, smoking, and cardiovascular disease history. Respondents with 
T2DM, HTN, and obesity had signiﬁcantly more physician visits (mean of 8 vs. 6, p 
= 0.001), especially 10 or more visits (21% vs. 15%), than respondents with T2DM 
only (p = 0.03). No signiﬁcant differences (p > 0.05) were reported for percentage 
hospitalized (21% vs. 20%) and number of days hospitalized (mean of 7 vs. 11 days) 
over the past 12 months. Respondents with comorbid HTN and obesity reported 
signiﬁcantly more ED visits (9% with 2–13 visits) compared with T2DM-only group 
(5% with 2–5 visits, p = 0.02). CONCLUSIONS: Respondents with comorbid condi-
tions of T2DM, HTN, and obesity have greater health care resource utilization in 
physician ofﬁce visits and ED visits than those with T2DM only.
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ARE DOUBLE-BLIND, DOUBLE-DUMMY STUDIES SUITABLE FOR 
RESOURCE UTILISATION ANALYSES? AN EXAMPLE FROM A NEW 
ORAL ANTICOAGULANT FOR THE PREVENTION OF VENOUS 
THROMBOEMBOLISM (VTE) FOLLOWING ORTHOPAEDIC SURGERY
Roskell N1, Wolowacz S1, Christiansen AV2, Plumb JM3
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Danmark A/S, Copenhagen 
OE, Denmark, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
OBJECTIVES: Resource utilisation data were collected in all three Dabigatran etexi-
late (DBG) Phase III primary VTE prevention following orthopaedic surgery studies. 
This study aimed to, within trial, summarise resource use by treatment group and 
compare resource use separately for each dose of orally-administered DBG (150 mg 
od, 220 mg od) versus subcutaneous enoxaparin. METHODS: The RE-MOBILIZE 
study included 2596 knee-surgery patients and compared DBG to enoxaparin 30 mg 
bid. The RE-MODEL and RE-NOVATE studies included 2076 and 3463 patients 
undergoing knee and hip surgery respectively, and compared DBG with enoxaparin 
40 mg od. All studies used a randomised, double-blind, double-dummy non-inferiority 
design. Duration of treatment differed by study. Data collected for all patients included 
hospitalisation (main and re-admission), non-protocoled diagnostics, blood transfu-
sions, reoperations, concomitant medications and health care contacts for enoxaparin 
injections. Each resource use category was summarised, separately for each study, by 
and between treatment using means and standard errors. Two sample t-tests were used 
to examine differences between treatments. RESULTS: There were no consistently 
signiﬁcant differences between treatments (within each study). The percentages of 
patients requiring domiciliary nurse visits to administer thromboprophylaxis following 
discharge from hospital (i.e. administer subcutaneous enoxaparin or placebo because 
the patient was unable to self-inject) were 5.6% (DBG 150 mg od), 5.0% (DBG 
220 mg od) and 5.4% (enoxaparin) in RE-MOBILIZE, 1.0%, 1.5% and 1.9% in 
RE-MODEL, and 4.4%, 5.1% and 5.0% in RE-NOVATE. All domiciliary nurse visit 
comparisons for each DBG arm versus enoxaparin were statistically non-signiﬁcant 
(P > 0.15). CONCLUSIONS: Double-blind, double-dummy study designs appear to 
be unhelpful in the identiﬁcation of differences that might arise from changes in treat-
ment formulation and route of administration. In this study, a hypothesised difference 
in domiciliary nurse treatment administrations remained undetected due to the double-
dummy nature of the trials.
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DISCRETE EVENT SIMULATION OF CARDIAC HOSPITALS PERFORMING 
PERCUTANEOUS CORONARY INTERVENTIONS
Pei P1, Kongnakorn T2, Hernández L3, Bae JP4, Ramaswamy K5, Moller J6
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OBJECTIVES: Efﬁcient facility operation is an important factor in quality of care for 
hospitals. How treatment protocols inﬂuences efﬁciency and productivity of a cardiac 
hospital is little known. METHODS: A discrete event simulation model of a cardiac 
hospital with percutaneous coronary intervention (PCI) capability was built on analy-
sis of time-stamped electronic medical record database (Cerner Health Facts®). Addi-
tional data were obtained from PCI literature, TRITON TIMI-38 trial, hospital 
statistics, and expert opinions. ACS treatment options include PCI, coronary arterial 
bypass graft (CABG), or drug therapy. Three oral antiplatelet dosing strategies for 
unstable angina (UA) and non-ST segment myocardial infarction (NSTEMI) were 
considered with loading dose given at PCI, minimum 2 hours prior, and minimum 6 
hours prior to PCI. Facility occupancy, wait, PCI volume, and length of stay, were 
tracked. RESULTS: Pre-treatment strategy increased patients’ total time in the hospital 
for all ACS-PCI, with an average time of 114.96 hours with loading dose at PCI, 
118.32 hours (+2.92%) with minimum 2 hours prior, and 121.68 hours (+5.85%) 
with minimum 6 hours prior. For UA/NSTEMI subgroup, total time in hospital was 
129.04 hours with loading at PCI, 134.51 hours (+4.24%) with minimum 2 hours 
prior, and 140.38 hours (+8.79%) with minimum 6 hours prior to PCI. Increase was 
mainly in pre-procedure time. Pre-treatment has no signiﬁcant effect on procedure 
times. Among the CABG-bound patients, pre-operation times increased by 33.49 
hours (+85.77%) and 35.47 hours (+90.83%) under 2 and 6 hour pre-treatment 
strategy, respectively. CONCLUSIONS: Pretreatment strategy with oral antiplatelet is 
likely to cause some inefﬁciency in hospital due to waits and longer total stay. This 
may increase facility congestion, occupancy, and staff hours. In CABG-bound patients, 
pretreatment leads to additional days due to recommended wait. The pretreatment 
strategy as a way to optimize antiplatelet therapy in ACS-PCI entails efﬁciency costs.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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CONCORDANCE AMONG THREE SELF-REPORTED MEASURES OF 
MEDICATION ADHERENCE AND COUNT OF TABLETS RECORDS IN 
COLOMBIAN HYPERTENSIVE PATIENTS
Garcia Vega OA, Buendia Rodriguez JA
Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: To evaluate the level of agreement among three previously validated 
self-reported medication adherence measures and count of tablets records METHODS: 
This was a cross-sectional study which included adult patients (40 and older) with 
hypertension disease enrolled continuously for 6 months in a private medical center. 
Random sequences of tests (communication of self-compliance (SC), Morinsky-Green 
Test (MG) and knowledge of the illness (KI)) were used to estimate the adherence of 
antihypertensive medication. Threshold of 80% was used to determine adherence with 
count of tablets. Concordances were assessed using Cohen’s kappa coefﬁcient (k) and 
prevalence-adjusted bias-adjusted kappa (PABAK). RESULTS: A total of 151 hyper-
tensive patients were included in the study. A total of 65.5% of these patients have 
other comorbilities and 45.6% took more than 5 drugs per day. The prevalence of 
non adherence, using a tablet count as reference test, was 8%. Due substantial imbal-
ance in the fourfold table’s marginal totals we found high agreement of negative results 
(SC (0, 94), MG (0.60), KI (0.72)) but low Kappa (SC (k:- 0,03), MG (k: 0,06), KI 
(k:−0,01)).The Kappa values adjusted (PABAK) were SC (k:0.79), MG (k: −0,06), KI 
(k:0,15). CONCLUSIONS: Because of the weak to moderate concordance found 
among validated measures of adherence, the selection of a useful adherence measure 
in clinical practice is difﬁcult. These ﬁndings underscore the difﬁculty in both assessing 
patients’ medication-taking behavior and assessing and comparing the results of adher-
ence research. The development of valid and reliable measures for easily assessing 
medication adherence behavior in clinical setting is needed.
PCV95
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DYSLIPIDEMIC MEDICATIONS USING PHARMACY AND MEDICAL 
CLAIMS DATA FROM A COMMERCIAL HEALTH PLAN
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OBJECTIVES: To develop predictive models for medication compliance in dyslipid-
emia that will aid health care decision makers in targeting compliance intervention 
programs. METHODS: Pharmacy and medical claims data from a commercial health 
plan were analyzed for all currently enrolled members who received their ﬁrst dyslip-
idemic medication between May 1, 2007 and April 30, 2008. Percentage of days 
covered (PDC) deﬁned as days supply of dyslipidemic medication per 365 days. PDC 
< 80% was used to categorize non-compliant patients. Potential independent variables 
included patient demographics, pharmacy utilization and medical conditions. Stepwise 
logistic regression was used to predict the odds of non-compliance. RESULTS: A total 
of 88,635 patients were included. Sixty-ﬁve percent of patients were non-compliant 
(PDC = 0.33; SD = 0.22). The most signiﬁcant predictor of non-compliance was treat-
ment with bile acid sequestrants (OR: 6.75; p < 0.0001, compared to statins). Signiﬁ-
cant predictors of non-compliance also included age category, increasing from an OR 
= 1.11 for age 45–55 to OR = 3.23 for age <18 [p < 0.0001 for all estimates compared 
to age 75+]; prior diabetes diagnosis (OR: 1.15, p < 0.0001) and the number of unique 
pharmacies used (OR = 1.10 per additional pharmacy; p < 0.0001). Factors reducing 
non-compliance include male gender (OR: 0.77, p < 0.0001); previous heart attack 
(OR: 0.82; p = 0.0221); prior compliant behavior (OR: 0.888; p < 0.0001); number 
of unique physicians seen for medications (OR: 0.969 per additional physician; p < 
0.0001) and copayment categories (relative to no copayment). Compliance signiﬁ-
cantly improved by 12%, 12% and 6% for copay categories $5–$10, $10–$20, and 
$20–$30, respectively to no copayment. (p < 0.01). CONCLUSIONS: The results may 
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be used by health care decision makers to identify patients who are most likely to be 
non-compliant with dyslipidemia therapy and help focus medication compliance 
efforts. A secondary analysis using corresponding lab data is projected.
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IMPACT OF MEDICARE PART D ON ADHERENCE AND PERSISTENCE 
WITH STATIN MEDICATIONS FOR TEXAS DUAL-ELIGIBLE 
BENEFICIARIES
Richhariya A, Shepherd MD
The University of Texas, Austin, Austin, TX, USA
OBJECTIVES: To compare dual-eligible patient out-of-pocket costs, adherence (medi-
cation possession ratio), persistence, and average number of gap days in therapy before 
and after Medicaid patients enrolled in Medicare Part D. METHODS: This study 
employed a quasi-experimental, repeated measures design. Study population included 
1734 Texas dual-eligible beneﬁciaries who had prescriptions ﬁlled in Texas indepen-
dent community pharmacies between January 2005 and September 30, 2006. 
RESULTS: Average patient out-of-pocket costs increased from $0.39 per claim under 
Medicaid to $13.36 per claim under Medicare Part D. Patient MPR increased from 
75.71% during the Medicaid period to 79.37% during the Medicare period. Linear 
mixed model analysis showed that patient’s MPR increased by 3.66% when patients 
were enrolled under Medicare. Patients were persistent to their drug therapy for an 
average of 151.76 days under Medicaid and days of persistence increased to 159.75 
days during the Medicare period. Linear mixed model analysis showed that patients 
were persistent for 7.99 extra days after they were enrolled in Medicare Part D. 
Average number of gap days in therapy during the Medicaid period was 11.91 days 
and decreased to 8.38 days during the Medicare period. Linear mixed model analysis 
showed that average number of gap days in therapy decreased by 3.52 days when 
patients were enrolled in Medicare Part D. Linear mixed model analysis and linear 
regression analysis showed that as patient out-of-pocket costs increased, patient medi-
cation possession ratio and persistence increased and average number of gap days in 
therapy decreased. CONCLUSIONS: These results suggest that dual-eligible beneﬁ-
ciary’s medication utilization increased after implementation of Medicare Part D. 
Based on these results it can be concluded that higher out-of-pocket costs for dual-
eligible beneﬁciaries under Medicare Part D did not have a negative impact on their 
drug adherence and persistence.
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ANALYSIS ON THE EFFECTS OF MEDICARE PART D COVERAGE GAP 
ON STATIN MEDICATION ADHERENCE
Pai J1, Zeng F2, Patel BV2, Sanchez RJ3, McCombs J1
1USC School of Pharmacy, Los Angeles, CA, USA, 2MedImpact Healthcare Systems, San 
Diego, CA, USA, 3Pﬁzer Inc., New York, NY, USA
OBJECTIVES: To investigate the impact of the coverage gap in the Medicare Part D 
program on statin medication adherence. METHODS: A pharmacy claims database 
from a national pharmacy beneﬁt management company was used for this retrospec-
tive analysis. The sample includes Medicare Part D patients 65 years and older who 
1) used statins in both 2007 and 2008, and 2) entered the coverage gap (donut hole), 
but did not reach the catastrophic phase in 2008. Adherence was measured by a 
dummy variable indicating whether the proportion of days covered was greater than 
or equal to 0.8. A difference-in-differences regression analysis was used to evaluate 
the effect of the coverage gap by comparing adherence to statins before and after the 
start of the donut hole. RESULTS: A total of 26,686 patients were identiﬁed. Beneﬁ-
ciaries were mostly women (55.5%) with an average age of 75 years. Patients in the 
study were divided into three groups based on level of coverage in the donut hole: no 
coverage (N = 4,984), generic drug coverage (N = 6,063), or generic and brand drug 
coverage (N = 15,639). After patients entered the donut hole, the average 30-day 
co-payment for statin medications increased notably for beneﬁciaries who had no drug 
coverage ($21.62 to $49.72) or generic only coverage ($22.22 to $42.04), but 
decreased for those with generic and brand drug coverage ($20.12 to $16.63) Com-
pared to beneﬁciaries with both generic and brand medication coverage, beneﬁciaries 
with no coverage (OR = 0.581, p < 0.0001, 95% CI 0.525–0.645) and beneﬁciaries 
with only generic medication coverage (OR = 0.662, p < 0.0001, 95% CI 0.601–0.728) 
were less likely to be adherent to statin medications after entering the donut hole. 
CONCLUSIONS: Medicare beneﬁciaries with no coverage or generic only coverage 
were less likely than those with a more comprehensive gap coverage to be adherent 
to statins after entering the donut hole.
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ADHERENCE TO LIPID LOWERING THERAPIES AS A PREDICTOR OF 
CHOLESTEROL OUTCOMES: A LITERATURE REVIEW
Uzoigwe C1, Tunceli K1, Hu X(2
1Merck, Whitehouse Station, NJ, USA, 2Merck, West Point, PA, USA
OBJECTIVES: Despite the beneﬁts of lipid lowering therapies (LLT), adherence to 
LLT remains poor. This review aims to summarize and assess evidence from prior 
research on the association between adherence to LLT and cholesterol outcomes 
(cholesterol levels and/or goal attainment). METHODS: We searched PubMed data-
base for research articles written in English and published between January 1, 2000 
and December 31, 2009 using combinations of the following terms: “adherence,” 
“compliance,” “statin,” and “lipid lowering”. Retrieved articles were included for 
review if they met the criterion of adherence/compliance as a predictor of cholesterol 
outcomes (e.g., LDL-C, HDL-C, or TC). RESULTS: The automated literature search 
yielded 527 studies, 8 of which met the inclusion criteria. Despite that a majority of 
studies examined adherence to LLT, only a few included cholesterol outcomes. A total 
of 519 studies were excluded: 340 for being off topic, 5 for having no adherence 
measure, and 174 for having no cholesterol measures reported as an outcome. This 
review initially sought to quantify the effect of adherence on cholesterol outcomes; 
however, adherence measures and methods varied greatly among the 8 studies and 
made data synthesis challenging. Heterogeneous methodologies were used for adher-
ence measures, including medication possession ratio (MPR), medication event moni-
toring system (MEMS), adherence to therapy index (ATI), continuous measure of 
medication gaps (CMG) and pill counting. Regardless of how adherence was deﬁned, 
better adherence was associated with improved cholesterol outcomes (lower LDL-C 
or TC or higher HDL-C levels compared to their respective baseline levels). CONCLU-
SIONS: Few studies evaluated both adherence to LLT and cholesterol outcomes and 
various methodologies were used for adherence measurements. Further studies assess-
ing compliance and objective clinical endpoints are needed. Health care providers 
should monitor medication adherence and develop effective interventions to improve 
adherence given the evidence on improved cholesterol outcomes as a result of increased 
adherence.
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THE ROLE OF ILLNESS BURDEN AND MEDICATION BELIEFS IN 
MEDICATION COMPLIANCE OF ELDERLY WITH HYPERTENSION
Rajpura JR, Nayak R
St.John’s University, Jamaica, NY, USA
OBJECTIVES: To measure the impact of illness burden and medication beliefs on 
medication compliance of elderly with hypertension using a tool that pictorially rep-
resents the burden of illness on self. METHODS: A cross-sectional research design, 
utilizing convenience sampling strategies and self-administered surveys of elderly 
hypertensive residents living in New York City senior care centers. Medication compli-
ance was measured using Morisky’s test, medication beliefs were measured using 
beliefs about medication questionnaire (BMQ), and illness burden was operationalized 
by implementing Pictorial Representation of Illness and Self Measure- Revised II 
(PRISM-RII) instrument. PRISM is a novel and visual measurement tool of suffering 
that consists of two components, namely, self illness separation (SIS) and illness 
perception measure (IPM).Additionally, two index scores, namely World Health Orga-
nization (WHO-5) wellbeing score and Suffering Question (SQ) scores were also 
computed to further examine interrelationships among study variables. RESULTS: 
About 33% of the 120 hypertensive elderly cohorts who responded to the survey were 
found to be noncompliant with their blood pressure medications. Morisky’s score 
correlated signiﬁcantly and positively with both BMQ differential scores (r = −0.303, 
p = 0.001) and SIS component scores (r = −0.425, p = 0.000) respectively. General 
Overuse (GO) scores and IPM component scores correlated positively with Morisky’s 
score (r = 0.347 & 0.440, p = 0.000). SIS correlated positively with WHO-5 (r = 
0.142, p = 0.126) and negatively with IPM (r = −0.841, p = 0.000). CONCLUSIONS: 
Beliefs about the beneﬁts of taking medications outweigh the costs and risks of taking 
them. Higher perceived illness burden in hypertension translates into lower medication 
compliance in elderly. PRISM-RII may be a useful measure of illness burden in compli-
ance research in elderly populations. The study underscores the importance of incor-
porating patient perceptions about medications and illness burden into decisions 
involving hypertension management.
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INTERVENTIONS TO IMPROVE COMPLIANCE WITH LIPID LOWERING 
MEDICATIONS: A SYSTEMATIC REVIEW OF THE LITERATURE
Zuluaga A1, Salas M2, Gwadry-Sridhar F3, Manias E4, Hughes D5
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OBJECTIVES: To identify the most effective interventions to improve patient compli-
ance with lipid lowering medications. METHODS: A systematic review was conducted 
using Medline, Cumulative Index to Nursing and Allied Health Literature, EMBASE, 
Cochrane Library, and references of review articles, and meta-analyses. Abstracts of 
studies published between 1999 and 2009, irrespective of language that included the 
terms: hyperlipidemia, hypercholesterolemia, lipid lowering medications and adher-
ence, compliance, and interventions were screened. Studies with incomplete informa-
tion, lack of adherence measure, overviews and letters to editors were excluded. Full 
articles of studies on interventions that reported the use of a comparator group and 
reported quantitative data on compliance were included. Two independent researchers 
reviewed papers, and disagreements were agreed by consensus. A standardized data 
extraction form was used to record details on study design, objectives, randomization, 
blinding, comparator group, type of intervention, outcomes, population, follow up, 
ethics approval, sample size, statistical analysis and results. A quality score was cal-
culated using the Downs modiﬁed scale. RESULTS: Of 130 titles, 79 abstracts were 
screened and only 15 studies fulﬁlled the inclusion criteria. Study heterogeneity pre-
cluded a quantitative meta-analysis. Most interventions improved drug compliance 
from 15% for single interventions to 27% for complex interventions. Most studies 
focused on pharmacist-led interventions, and the most effective included the use of 
telephone reminders, card reminders, brochures, and booklets. All interventions were 
able to reduce LDL and/or total cholesterol. Average index quality score was 40%. 
CONCLUSIONS: Interventions focused on improving compliance reduce LDL and 
total cholesterol. The most effective interventions to improve compliance with lipid 
lowering medications are complex, multi-factorial interventions. However, reports 
have variable quality.
